Vyxeos liposomal is a cancer medicine used to treat adults with newly diagnosed acute myeloid leukaemia, a cancer of white blood cells. It is used when the leukaemia was caused by previous treatments (e.g. for other cancers) or is associated with certain changes in the bone marrow known as myelodysplasia. The active substances in Vyxeos liposomal are daunorubicin and cytarabine.
Therapeutic Indication
### Therapeutic indication Vyxeos liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Therapeutic Area (MeSH)
ATC Code
L01XY01
ATC Item
cytarabine and daunorubicin
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
EMA Name
Vyxeos liposomal (previously known as Vyxeos)
Medicine Name
Vyxeos liposomal (previously Vyxeos)
Aliases
N/A